Due to the rapidly developing nature and severity of the COVID-19 pandemic, clinical trials
involving a repurposed drug approach are the best option for rapidly identifying an effective
COVID-19 therapeutic. The investigators propose to evaluate the efficacy of Montelukast in
attenuating cytokine storm syndrome and ARDS via a randomized, blinded, placebo-controlled
clinical trial. Specifically, our primary objective is comparing the efficacy of low-dose
Montelukast versus placebo in reducing the risk of acute care visits and hospital admissions
among COVID-19 positive patients in the general population.